Original Article Japanese Urological Association. International Journal of Urology (2006) 13,
|
|
- Rosemary Wilkins
- 6 years ago
- Views:
Transcription
1 Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology Blackwell Publishing Asia Pty Ltd Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo et al. International Journal of Urology (2006) 13, doi: /j x Original Article Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia DJOKO RAHARDJO, 1 DODDY M SOEBADI, 2 SUWANDI SUGANDI, 3 PONCO BIROWO, 1 WAHJOE DJATI 2 AND IRFAN WAHYUDI 3 1 Subdivision of Urology, Department of Surgery University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, 2 Department of Urology Airlangga University, Sutomo Hospital, Surabaya, and 3 Subdivision of Urology, Department of Surgery Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia Aim: The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Methods: The safety and efficacy of tamsulosin (0.2 mg) and doxazosin (2 mg) was determined after once daily administration for 6 weeks in an open-label, randomized, multicenter study of 101 men with BPH. The International Prostatic Symptom Score (IPSS), maximal urinary flow rates (Qmax), average urinary flow rates (Qave) and residual urine were determined at baseline and again at 6 weeks as efficacy parameters. The primary parameters used for safety evaluation were vital signs (blood pressure and heart rate) and adverse events. The number of patients with a clinically significant response to treatment with tamsulosin or doxazosin was determined and defined as those with >20% improvement from the baseline Qmax or >20% decrease in total IPSS. Results: The total IPSS decreased significantly in both the tamsulosin and doxazosin groups compared to baseline. There was a significant difference in the decrease in total IPSS between two groups. Qmax, Qave and residual urine significantly improved only in the tamsulosin group. There were no significant differences in systolic blood pressure, diastolic blood pressure or heart rate profile in the tamsulosin group; however, doxazosin resulted in a significant difference in systolic and diastolic blood pressure. Tamsulosin was well tolerated; only three patients (6%) in the tamsulosin group reported an adverse event (dizziness) while 11 patients (22%) in the doxazosin group reported an adverse event (dizziness), one of whom withdrew from the study. Conclusions: Tamsulosin was shown to be more effective than doxazosin in the treatment of LUTS due to BPH. Key words benign prostatic hyperplasia, doxazosin, lower urinary tract symptoms, tamsulosin. Introduction Lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH) is a very common condition among older men throughout the world with approximately 25% of men over the age of 40 suffering from LUTS. 1,2 Selective alpha-1-adrenoceptors inhibit sympathetic stimulation of prostatic smooth muscle, thereby reducing prostatic tone and relieving urinary obstruction. Clinical studies with alpha-blockers (alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have demonstrated a significant beneficial effect on symptoms and uroflow. 3 Caine et al. proposed a hypothesis for the use of alphablockers in the treatment of bladder outlet obstruction due to BPH in By antagonizing the effect of noradrenaline at the alpha-1-adrenoceptor, the alpha-blockers Correspondence: Ponco Birowo MD, Subdivision of Urology, Department of Surgery, University of Indonesia, Cipto Mangunkusumo Hospital, Jl. Diponegoro no. 71, Jakarta 10430, Indonesia. ponco.birowo@gmail.com Received 8 December 2005; accepted 18 May reduce smooth muscle cell tone in the bladder neck, prostatic urethra, prostate capsule and prostatic adenoma (stroma) and, consequently, reduce the dynamic component of bladder outlet obstruction. 4 7 Thus, the short-acting alpha-1-blockers and the long-acting alpha-1-blockers (e.g. doxazosin) are effective in treating hypertension and in patients with symptomatic BPH. They improve symptoms and urinary flow rate and a favorable clinical response is achieved in about 70% of patients. 4,5 Although effective in reducing the muscle tone resulting in better urine flow, side-effects such as dizziness and a decrease in blood pressure have been reported. 8 Tamsulosin is known to have numerous advantages and disadvantages over doxazosin. Both tamsulosin and doxazosin offer significant improvement in symptom score and peak urinary flow rate. There is an increased incidence of ejaculatory dysfunction in patients receiving tamsulosin, while doxazosin is associated with a significantly raised incidence of dizziness, hypotension and asthenia. 3 It is important therefore to compare tamsulosin with other alpha blockers to evaluate the advantages and disadvantages of its use.
2 1406 D Rahardjo et al. The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with LUTS due to BPH. Methods Patients This 6-week, randomized, open label, multicenter study was authorized by the Institutional Review Board of the University of Indonesia, Airlangga University and Padjadjaran University. The study population was made up from male outpatients with LUTS due to BPH who visited the urology clinics at Cipto Mangunkusumo Hospital, Jakarta, Central Pertamina Hospital, Jakarta, Hasan Sadikin Hospital, Bandung, and Sutomo Hospital, Surabya. All subjects enrolled in the study met the inclusion and exclusion criteria. Subjects were informed of the details of the study by the study investigators, and also of possible adverse effects including ejaculatory dysfunction as well as dizziness, hypotension or asthenia, and all subjects gave their written informed consent to participate in the study. Subjects with moderate to severe symptomatic BPH were selected for enrollment in the study. BPH was diagnosed from patient history, symptoms, digital rectal examination and transrectal ultrasonic imaging. The inclusion criteria were men aged 40 years or over, with International Prostatic Symptom Score (IPSS) total symptom score of 13 or higher, maximum urinary flow rate (Qmax) 4 15 ml/s, voided volume 120 ml or higher, PSA level less than 8 ug/ml, residual urine <100 ml and prostate volume of less than 60 ml. The exclusion criteria were subjects who underwent prostatectomy during the period of 3 months prior to this study, concomitant neurogenic bladder, bladder neck sclerosis, urethral stricture, prostatic cancer, cystolithiasis, severe vesical diverticulum and urinary tract infection. Also excluded were those with severe hepatic or renal dysfunction, severe cardiovascular disorder, orthostatic hypotension, or senile dementia, subjects with a history of drug hypersensitivity or allergy to tamsulosin and doxazosin, and subjects with any other conditions that may result in voiding dysfunction. The number of patients with a clinically significant response to treatment with tamsulosin or doxazosin was determined and defined as improvement of more than 20% over baseline in Qmax or a total IPSS decrease of more than 20%. Possible and probable adverse events considered related to the medication were recorded during the course of treatment period. Intention-to-treat (ITT) analysis was performed. Study design Subjects were randomized into two groups, one receiving tamsulosin 0.2 mg daily orally after breakfast and the other doxazosin 2 mg daily orally before sleep for 6 weeks. Prior to the active treatment, the subjects underwent a 2-week wash-out period if they were given no medication for BPH. If the subjects were still being treated for BPH on the day of their first study visit, the wash out period was a minimum of 4 weeks. In the wash-out period the subjects were given no medication for BPH. Efficacy and safety were monitored every 2 weeks for all evaluated subjects in both groups. The primary parameters for assessment of efficacy were IPSS, Qmax, average urinary flow (Qave) and residual urine. Other baseline parameters included, age, weight, height, prostate specific antigen (PSA), and prostate volume, which was assessed by transrectal ultrasound. The primary parameters for assessment of safety were vital signs (blood pressure and heart rate) and adverse events. At every visit, the patients were asked about and assessed for any adverse events that had possibly occurred. Statistical analysis The baseline characteristics of the patients in both groups and differences in subjective and objective changes between the baseline and treatment periods were analyzed using the Student s t-test. Inter- and intra-group differences were evaluated using analysis of variance (ANOVA). The incidence of adverse events was analyzed by Fischer s exact test. All statistical analysis was performed using SPSS 12.0 (SPSS, Chicago, IL, USA). Statistical differences were considered significant at P < Results One hundred and nine patients were screened, of whom eight patients were excluded due to abnormal PSA (six patients), hematuria (one patient) and bladder stone (one patient). Therefore, 101 patients were enrolled and randomized into two treatment groups (50 patients in the tamsulosin group and 51 patients in the doxazosin group). Patient demographics and baseline characteristics for age, weight, total IPSS, Qmax, Qave, prostate volume, and PSA level are presented in Table 1. There were no significant differences between the two groups in any baseline parameters. Efficacy The efficacy data refer to the ITT population. The total IPSS after 6 weeks of treatment had decreased significantly in both the tamsulosin and doxazosin groups compared to baseline. However, there was a significant difference in the total IPSS decrease after 6 weeks of treatment between the two groups. The Qmax, Qave and residual urine after 6 weeks treatment were significantly improved only in the tamsulosin group (Table 2). Safety There was no significant difference in systolic blood pressure, diastolic blood pressure or heart rate profile after 6 weeks of treatment in the tamsulosin group compared to baseline. However, there was a significant difference in the doxazosin group in both systolic and diastolic blood pressure after treatment compared to baseline. The only adverse event noted in the study was dizziness (Table 3). Tamsulosin was well tolerated, with dizziness observed in three patients (6%) while in the doxazosin group 11 patients (22%) reported dizziness, one of whom discontin-
3 Tamsulosin vs doxazosin in BPH 1407 Table 1 Baseline characteristics of men with benign prostatic hyperplasia according to treatment group Characteristic Tamsulosin (n = 50) Doxazosin (n = 51) Total (n = 101) P-value* Age (years) 63.7 ± ± ± Weight (kg) 63.4 ± ± ± Height (cm) ± ± ± IPSS total score (0 35) 18.6 ± ± ± Maximum urinary flow rate (ml/s) 9.9 ± ± ± Average urinary flow rate (ml/s) 4.5 ± ± ± Prostate volume (ml ) 32.6 ± ± ± Prostate-specific antigen level (ng/ml) 2.3 ± ± ± Data expressed as mean ± SD. *Student s t-test; estimated by transrectal ultrasonography. IPSS, International Prostatic Symptom Score. Table 2 Mean and percentage change from baseline of efficacy parameters Parameter Tamsulosin Doxazosin P-value IPSS (0 35) Baseline 18.6 ± ± weeks 13.3 ± (28.4)** 14.5 ± (22.9)** weeks 11.0 ± (40.1)** 12.9 ± (31.4)** weeks 9.4 ± (49.4)** 11.6 ± (38.2)** Qmax (ml/s) Baseline 9.9 ± ± weeks 12.6 ± (27.2)** 11.3 ± (6) NS Qave (ml/s) Baseline 4.5 ± ± weeks 5.7 ± (22.8)** 5.0 ± (2) NS Residual urine (ml) Baseline ± weeks (18.7)* 44.2 ± (4.5) NS Statistical significance within groups (paired student s t-test): *P < 0.05 vs baseline; **P < 0.01 vs baseline. Statistical significance between groups (ANOVA). IPSS, International Prostatic Symptom Score; NS, not significant; Qave, average urinary flow rate; Qmax, maximum urinary flow rate. ued the study as they could not tolerate the adverse event. The difference in the incidence of adverse events between the two groups was significant (P < 0.05; Table 4). Discussion To our knowledge there is no prior published study that has directly compared the efficacy and safety of tamsulosin 0.2 mg daily and doxazosin 2 mg daily in the treatment of BPH. The results of this study confirmed the efficacy of tamsulosin and doxazosin in patients with BPH. After 6 weeks of treatment, there was a clinically and statistically significant decrease in total IPSS in both groups compared to baseline. In the tamsulosin group, the total IPSS had decreased by 49.4% compared to baseline, while in the doxazosin group the decrease was 38.2%. This finding was clinically and statistically significant as the difference was more than 20% and P < A statistically significant difference therefore exists between the two treatment groups. This result was better than that obtained by Lee, who previously reported a decrease of 34.7% for tamsulosin. 9 However, the results for the doxazosin group were similar to data from a previous study published by Fawzy et al. who reported a decrease of 39% in total IPSS, 10 while another study reported a decrease of 30 45%. 11 A clinically and statistically significant improvement in Qmax and Qave compared to baseline were only observed in the tamsulosin group with improvements of 27.7% and 22.8%, respectively. The improvement in the doxazosin group for Qmax was only 0.7% while for Qave there was a slight decrease ( 0.1%). These results were not as significant as those previously reported, which found an improvement in Qmax of 30 35% for the tamsulosin group 12,13 and 20 36% for doxazosin group. 14,15 These differences are probably due to the duration of the study and the dose of the drugs administered.
4 1408 D Rahardjo et al. Table 3 Mean and percentage change from baseline of safety parameters Parameter Tamsulosin Doxazosin P-value Systolic blood pressure (mmhg) Baseline ± ± weeks ± (0.8) NS ± (1.7) NS weeks 6 weeks ± ± (0.5) NS 0.7 (0.5) NS ± ± (4.6)** 5.6 (4.0)** Diastolic blood pressure (mmhg) Baseline 82.2 ± ± weeks 81.2 ± (1.2) NS 80.7 ± (4.7)* weeks 82.0 ± (0.2) NS 80.3 ± (5.2)* weeks 82.2 ± (0) NS 82.0 ± (3.2) NS Heart rate (b.p.m.) Baseline 78.8 ± ± weeks 78.1 ± (0.9) NS 80.1 ± (2.4) NS weeks 78.6 ± (0.2) NS 79.8 ± (2.0) NS weeks 78.7 ± (0.1) NS 78.4 ± (0.3) NS Statistical significance within groups (paired Student s t-test): *P < 0.05 vs baseline; **P < 0.01 vs baseline. Statistical significance between groups (ANOVA). NS, not significant (P > 0.05). Table 4 Incidence of adverse events Tamsulosin Doxazosin Number of patients Incidence of adverse events 3 (6) 11 (22)* (Dizziness) Discontinuation due to adverse events 0 1 *P < 0.05, significantly different from the values in the tamsulosin group (Fisher s exact test). Data expressed as n (%). The duration of this study was 6 weeks, while previous studies have run for 12 weeks or more, with one study lasting a year. 15 A 6-week treatment phase was employed in this study as we wanted to investigate the rapid response of the drugs and to prevent a high number of dropouts. A 6-week treatment phase was also employed in studies conducted in other Asian countries (Japan and China). They were able to observe the improvement of IPSS and Qmax in a 6-week treatment phase or in an even shorter period (4 weeks) The dosages of tamsulosin and doxazosin administered in our study were 0.2 and 2 mg, respectively. In previous studies, the dose of tamsulosin was 0.4 mg or 0.8 mg, 12,13 and for doxazosin it was 4 mg or 8 mg. 14,15 Our study showed a significant decrease in residual urine in the tamsulosin group but not in the doxazosin group. No significant changes in residual urine volume had previously been reported for either drug. 19 There were no significant differences in blood pressure or heart rate in tamsulosin group compared to baseline. This result was similar to previously published data, which also indicated no significant difference in blood pressure in normotensive, controlled hypertensive and uncontrolled hypertensive patients taking tamsulosin. 20,21 In a previous 4-year study, tamsulosin showed a small influence on the mean diastolic blood pressure both in supine and standing positions compared with baseline, but no influence on systolic blood pressure or heart rate in supine and standing positions compared with baseline. 22 In the doxazosin group, there was a significant difference in both systolic and diastolic blood pressure but not in heart rate compared to baseline. The difference in diastolic blood pressure was present after 4 and 6 weeks with P < 0.001, whereas for systolic blood pressure, the difference was observed at both 2 and 4 weeks with P < This result is similar to that from a previous study that found a significant difference in blood pressure in a hypertensive population, 23,24 but not in a normotensive population. 25 The only adverse event reported in the study was dizziness, although in the informed consent process, the possibility of other adverse events such as hypotension and ejaculatory dysfunction was also explained in detail. Dizziness was observed in three patients (6%) in the tamsulosin group and 11 patients (22%) in the doxazosin group. The adverse event rate in the doxazosin group is significantly higher than in the tamsulosin group (P < 0.05). Previously reported adverse events for tamsulosin include dizziness, nausea, palpitations, headache, lassitude, hypotension, drowsiness, dry mouth, rash, retrograde ejaculation, depression, impotence, malaise, and pruritus. These adverse events were reported in 226 of the patients enrolled in that study. 26 The fact that there were no discontinuations in the tamsulosin group indicates the high safety and tolerability of tamsulosin. This is probably related to the dose of tamsulosin of only 0.2 mg and the duration of the study of only 6 weeks. Previously reported adverse events for doxazosin have included dizziness,
5 Tamsulosin vs doxazosin in BPH 1409 headache, hypotension, peripheral edema, somnolence, fatigue, nausea, palpitations, abdominal pain, abnormal vision, asthenia and chest pain, with the incidence of the adverse events due to doxazosin ranging from 16 to 48%. 10,14,23,24 In conclusion, tamsulosin was shown to be more effective than doxazosin in the treatment of LUTS due to BPH. The tamsulosin group had a significant improvement in Qmax and Qave compared to the doxazosin group. There was an improvement in residual urine in the tamsulosin group compared to baseline, while in the doxazosin group there was no significant difference. In addition, tamsulosin had less of an adverse impact on blood pressure than doxazosin and was well tolerated. Acknowledgment This study was supported by Yamanouchi Pharmaceutical Co., Ltd, Japan. References 1 Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 1993; 150: Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol. 2000; 38: Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br. J. Urol. 1976; 48: Lepor H. Medical therapy for benign prostatic hyperplasia. Urology 1993; 42: Lepor H. The treatment of benign prostatic hyperplasia with alpha1 blockers. Curr. Opin. Urol. 1994; 4: Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin. Proc. 1993; 68: Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double blind, placebo-controlled, dose response multicenter study. J. Urol. 1995; 154: Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptom associated with benign prostatic hyperplasia in Korean patients. J. Int. Med. Res. 2002; 30: Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol. 1995; 154: Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha1- adrenoceptor antagonists. BJU Int. 2005; 95: Arnold EP. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand. BJU Int. 2001; 87: Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States Study Group. J. Urol. 1998; 160: de Reijke TM, Klarskov P. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int. 2004; 93: Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: Okada H, Kamidono S, Yoshioka T et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int. 2000; 85: Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int. J. Urol. 2000; 7: Li NC, Chen S, Yang XH, Du LD, Wang JY, Na YQ. Efficacy of low dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin. Drug Invest. 2003; 23: Eri LM, Tveter KJ. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 1995; 154: Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: Schulman CC, Lock TM, Buzelin JM et al. Long-term use of tamsulosin to treat lower urinary tract symptom/benign prostatic hyperplasia. J. Urol. 2001; 166: Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a doubleblind, placebo-controlled, dose response multicenter study. J. Urol. 1995; 154: Kaplan SA, Kaplan NM. Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia. Urology 1996; 48: Kaplan SA, D alisera PM, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: Mann RD, Biswas P, Freemantle S, Pearce G, Wilton L. The pharmacovigilance of tamsulosin: event data on patients. BJU Int. 2000; 85:
The Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationa 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia
Single dose methodology to assess the in uence of an a 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia S. P. Curtis, 1 I. Eardley, 2 M. Boyce, 3 P. Larson,
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationA Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationInternational Clinical Development Department, Yamanouchi Pharmaceutical Co., Ltd., 17 1 Hasune 3-chome, Itabashi-ku, Tokyo , Japan
192 Journal of Health Science, 47(2) 192 22 (21) Investigation of the Effects of Tamsulosin on Blood Pressure in Normotensive, Controlled Hypertensive, and Uncontrolled Hypertensive Men with Benign Prostatic
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationTamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
J. Acad. Indus. Res. Vol. 1(11) April 2013 679 RESEARCH MANUSCRIPT ISSN: 2278-5213 Tamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationThe treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years
British Journal of Urology (1997), 8, 875 879 The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 8 years S.A. KAPLAN, A.E. TE, E. IKEGUCHI and R.P. SANTAROSA Department
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationVoiding Dysfunction. Hyo Serk Lee, Sae Woong Kim 1, Seung-June Oh 2, Myung-Soo Choo 3, Kyu-Sung Lee
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.3.178 Voiding Dysfunction Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationÉZER A. MELO, DEMERVAL MATTOS JR., LUIS A. S. RIOS. Division of Urology, Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 28 (1): 25-32, January - February, 2002 A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, TO
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationEfficacy and safety of tamsulosin OCAS
Original Article EFFICACY AND SAFETY OF TAMSULOSIN OCAS SPEAKMAN Efficacy and safety of tamsulosin OCAS MARK SPEAKMAN Taunton and Somerset Hospital, Taunton, UK The efficacy and safety of a new tablet
More informationBenign Prostatic Hypertrophy (BPH) is the most
Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationEffects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2014 August 32(2): 99-104 http://dx.doi.org/10.5534/wjmh.2014.32.2.99 Original Article Effects of Tamsulosin on Premature Ejaculation in Men with
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationHee Young Park, Joo Yong Lee, Sung Yul Park, Seung Wook Lee, Yong Tae Kim, Hong Yong Choi, Hong Sang Moon
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.2.92 Voiding Dysfunction Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal
More informationShrestha A, Chalise PR, Sharma UK, Gyawali PR, Shrestha GK, Joshi BR. Department of Surgery, TU Teaching Hospital, Maharajgunj, Kathmandu, Nepal
Original Article Intravesical Prostatic Protrusion is better than Prostate Volume in Predicting Symptom Severity in Benign Prostatic Hyperplasia: A Prospective Clinical Study Shrestha A, Chalise PR, Sharma
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationEffects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.10.697 Sexual Dysfunction/Male Infertility Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationEjaculation. Emission. Ejection. Orgasm
Ejaculation Emission Ejection Orgasm Ejaculation sc T10-L2 S2-4 Emission: vas deferens, prostate, bladder neck Post. Urethra distention Ejection: Pelvic Floor / bulbocavernous muscle contraction Orgasm:
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationProstate Health PHARMACIST VIEW
Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationManagement of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005
Management of Voiding Problems in Older Men Dr. John Fenn Consultant, QEH 10 th October, 2005 Voiding Problems Poor stream Hesitancy Straining Incomplete emptying Intermittent micturition Terminal dribbling
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationSILOFAST Capsules (Silodosin)
Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each
More informationURIMAX Capsules (Tamsulosin hydrochloride)
Published on: 22 Sep 2014 URIMAX Capsules (Tamsulosin hydrochloride) Composition URIMAX-0.2 Capsules Each capsule contains: Tamsulosin Hydrochloride... 200 mcg (as modified-release pellets) URIMAX-0.4
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationCan men with prostates sized 80 ml or larger be managed conservatively?
Original Article - Lower Urinary Tract Dysfunction Investig Clin Urol 2017;58:359-364. pissn 2466-0493 eissn 2466-054X Can men with prostates sized 80 ml or larger be managed conservatively? Alvin Lee,
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationEffect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic Study
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.12.840 Voiding Dysfunction/Female Urology Effect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic
More informationBenign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care
Volume 1, Number 1 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and Prostate Health,
More informationEuropean Urology Supplements 4 (2005) 33 44
European Urology Supplements European Urology Supplements 4 (2005) 33 44 Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower UrinaryTract Symptoms Suggestive of Benign Prostatic
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationAn Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms
Case Report INJ 2010;14:125-129 An Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms Joo-Yong Lee, Dong-Hyuk Kang, Hee-Young Park, Jung-Soo Park, Young-Woo Son, Hong-Sang
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians
Therapeutic Advances in Chronic Disease Review The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians Neal Shore and Barrett Cowan Ther Adv Chronic Dis (2011) 2(6) 377 383
More informationInvestigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
Sakata and Morita BMC Urology 2012, 12:29 RESEARCH ARTICLE Open Access Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia Koichi Sakata 1* and Tatsuo Morita 2
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationThe Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
J Prev Med Public Health 2009;42(3):165-170 DOI: 103961/jpmph2009423165 The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia Joongyub Lee 1) Nam-Kyoung Choi 13) Sun-Young
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationManagement of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in Jakarta
Original Article Prostate Int 2014;2(2):97-103 P ROSTATE INTERNATIONAL Management of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in Jakarta Faisal
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationEuropean Urology 44 (2003) 89 93
European Urology European Urology 44 (2003) 89 93 Long-Term Evaluation of Transurethral Needle Ablation of the Prostate (TUNA) fortreatment of Symptomatic Benign Prostatic Hyperplasia: Clinical Outcome
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationINTRODUCTION MISCELLANEOUS
MISCELLANEOUS Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial Hossein Karami*, Amin Hassanzadeh-Hadad,
More informationGuideline for the primary care management of male lower urinary tract symptoms
review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationProfile of Silodosin. Francesco Montorsi * Article info. Abstract
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 491 495 available at www.sciencedirect.com journal homepage: www.europeanurology.com Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationInfluence of body mass index on Benign Prostatic Hyperplasia-related complications in patients undergoing prostatectomy
Mosli and Mosli SpringerPlus 2013, 2:537 a SpringerOpen Journal CASE STUDY Open Access Influence of body mass index on Benign Prostatic Hyperplasia-related complications in patients undergoing prostatectomy
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alfuzosin HCl Ranbaxy 10 mg tablets, prolonged-release tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationVoiding Dysfunction. Joon Seok Kwon, Jung Woo Lee 1, Seung Wook Lee, Hong Yong Choi, Hong Sang Moon. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2011.52.4.269 Voiding Dysfunction Comparison of Effectiveness of Monopolar and Bipolar Transurethral Resection of the Prostate and Open Prostatectomy in Large Benign Prostatic
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationBenign Prostatic Hyperplasia (BPH) IPT VI Srikanth Kolluru, Ph.D
Benign Prostatic yperplasia (BP) IPT VI Srikanth Kolluru, Ph.D. kolluru@tamhsc.edu, 361 221 0741 verview 1. Introduction and background of BP 2. Causes and common symptoms 3. Treatment options Learning
More informationLasers in Urology. Sae Woong Choi, Yong Sun Choi, Woong Jin Bae, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae Kon Hwang, Sae Woong Kim
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.12.824 Lasers in Urology 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in
More information